Scandinavian Biopharma secures €10.6 million from EDCTP for a Phase III trial of ETVAX® in children in low- and middle-income countries

Scandinavian Biopharma has been awarded a €10.6 million grant from EDCTP in international competition for the planned Phase III clinical trial of the ETEC vaccine candidate ETVAX®. The EDCTP grant is a part of the European Framework Programme for Research and Innovation, Horizon 2020. The project will include the development and manufacturing of an all-in-one […]